Glaxo May Begin Testing ‘Promising’ Ebola Vaccine in Humans
2014-08-11 15:16:09.812 GMT
By Oliver Staley
Aug. 11 (Bloomberg) -- GlaxoSmithKline is developing an
Ebola vaccine and is discussing starting phase 1 trials on human
subjects with regulators and the World Health Organization, the
company said in an e-mailed statement.
* Trials may begin this year.
* Animal trial results have been “promising,” according to
GSK statement
NOTE: GSK acquired the vaccine after buying Swiss-based biotech
company Okairos last year NOTE: Spain Imports Ebola Drug to
Treat Priest as Ethicists Weigh Use
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Oliver Staley in London at +44-20-3216-4369 or
ostaley@bloomberg.net
To contact the editors responsible for this story:
Phil Serafino at +33-1-5530-6277 or
pserafino@bloomberg.net
Robert Valpuesta, Kristen Hallam
2014-08-11 15:16:09.812 GMT
By Oliver Staley
Aug. 11 (Bloomberg) -- GlaxoSmithKline is developing an
Ebola vaccine and is discussing starting phase 1 trials on human
subjects with regulators and the World Health Organization, the
company said in an e-mailed statement.
* Trials may begin this year.
* Animal trial results have been “promising,” according to
GSK statement
NOTE: GSK acquired the vaccine after buying Swiss-based biotech
company Okairos last year NOTE: Spain Imports Ebola Drug to
Treat Priest as Ethicists Weigh Use
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Oliver Staley in London at +44-20-3216-4369 or
ostaley@bloomberg.net
To contact the editors responsible for this story:
Phil Serafino at +33-1-5530-6277 or
pserafino@bloomberg.net
Robert Valpuesta, Kristen Hallam